Read by QxMD icon Read


Delphine Rea, Shanti Ame, Marc Berger, Jean-Michel Cayuela, Aude Charbonnier, Valérie Coiteux, Pascale Cony-Makhoul, Viviane Dubruille, Stéphanie Dulucq, Gabriel Etienne, Laurence Legros, Franck Nicolini, Catherine Roche-Lestienne, Martine Escoffre-Barbe, Martine Gardembas, Agnès Guerci-Bresler, Hyacinthe Johnson-Ansah, Françoise Rigal-Huguet, Philippe Rousselot, François-Xavier Mahon
BACKGROUND: The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off-treatment response after treatment discontinuation; this situation is called treatment-free remission (TFR). Knowledge accumulated during the last 10 years justifies moving TFR strategies from research to clinical practice. METHODS: Twenty experts from the French Chronic Myeloid Leukemia Study Group (France Intergroupe des Leucémies Myéloïdes Chroniques), including 17 hematologists, 2 molecular biologists, and 1 cytogeneticist, critically reviewed published data with the goal of developing evidence-based recommendations for TKI discontinuation in clinical practice...
May 3, 2018: Cancer
Sylvain Carras, Benjamin Dubois, Delphine Senecal, Jean-Philippe Jais, Michel Peoc'h, Philippe Quittet, Charles Foussard, Krimo Bouabdallah, Thomas Gastinne, Eric Jourdan, Laurence Sanhes, Marjan Ertault, Thierry Lamy, Lysiane Molina
BACKGROUND: Patients with advanced stage Hodgkin lymphoma still present unsatisfactory outcomes. PATIENTS AND METHODS: The Groupe d'étude des Leucémies Aigues et des Maladies du Sang (GOELAMS) group conducted a prospective multicentric trial (NCT00920153) for advanced stage Hodgkin lymphoma to evaluate a positron emission tomography (PET)-adapted strategy. Patients received an intensive regimen (VABEM [vindesine, doxorubicin, carmustine, etoposide, and methylprednisolone]) in front-line and interim 18F FDG-PET evaluation after 2 courses (PET-2)...
March 2018: Clinical Lymphoma, Myeloma & Leukemia
Francis Lacombe, Lydia Campos, Kaoutar Allou, Christine Arnoulet, Adrienne Delabarthe, Florent Dumezy, Jean Feuillard, Franck Geneviève, Estelle Guérin, Julien Guy, Hélène Jouault, Pascale Lepelley, Marc Maynadié, Françoise Solly, Orianne Wagner Ballon, Claude Preudhomme, André Baruchel, Hervé Dombret, Norbert Ifrah, Marie C Béné
The assessment of minimal residual disease (MRD) in acute myeloblastic leukemia is of growing interest as a prognostic marker of patients' outcome. Multiparameter flow cytometry (MFC), tracking leukemia-associated immunophenotypic patterns, has been shown in several studies to be a useful tool to investigate MRD. Here, we report a multicenter prospective study which allowed to define a harmonized analysis strategy, as well as the efficacy of MFC MRD to predict outcome. This study included 276 patients, in 10 different MFC centers, of whom 268 had at least 1 MRD check point...
April 2018: Hematological Oncology
(no author information available yet)
After a cycle of meetings and discussions, members of the French Groupe d'Etude Immunologique des Leucémies obtained consensus on a series of immunophenotyping panels for hematological malignancies. The rationale of the markers chosen is depicted for each of them. This proposal comes for instruments with 8 or 10 colors. Care was taken to minimize the fluorochromes attached to any given specificity and to leave, whenever possible, some free slots for the cytometrist's choice.
November 21, 2017: Cytometry. Part B, Clinical Cytometry
A Sirvent, P Auquier, C Oudin, Y Bertrand, S Bohrer, P Chastagner, M Poirée, J Kanold, S Thouvenin, Y Perel, D Plantaz, M-D Tabone, K Yakouben, V Gandemer, P Lutz, N Sirvent, C Vercasson, J Berbis, H Chambost, G Leverger, A Baruchel, G Michel
Data on post-transplant iron overload (IO) are scarce in pediatrics. We conducted a prospective multicenter cohort study (Leucémie de l'Enfant et de l'Adolescent cohort) to determine the prevalence and risk factors of IO in 384 acute leukemia survivors transplanted during childhood. Prevalence of IO (ferritin level ⩾350 ng/mL) was 42.2% (95%CI 37.2-47.2%). Factors significantly associated with IO were: 1) in univariate analysis: older age at transplant (P<0.001), allogeneic versus autologous transplantation (P<0...
January 2017: Bone Marrow Transplantation
Sophie Piperno-Neumann, Marie-Cécile Le Deley, Françoise Rédini, Hélène Pacquement, Perrine Marec-Bérard, Philippe Petit, Hervé Brisse, Cyril Lervat, Jean-Claude Gentet, Natacha Entz-Werlé, Antoine Italiano, Nadège Corradini, Emmanuelle Bompas, Nicolas Penel, Marie-Dominique Tabone, Anne Gomez-Brouchet, Jean-Marc Guinebretière, Eric Mascard, François Gouin, Aurélie Chevance, Naïma Bonnet, Jean-Yves Blay, Laurence Brugières
BACKGROUND: Based on preclinical data for the antitumour effect of zoledronate in osteosarcoma, we assessed whether zoledronate combined with chemotherapy and surgery improved event-free survival in children and adults with osteosarcoma. METHODS: In this randomised, multicentre, open-label, phase 3 trial (OS2006), patients aged between 5 years and 50 years with newly diagnosed high-grade osteosarcoma were randomly assigned to receive standard chemotherapy with or without ten zoledronate intravenous infusions (four preoperative and six postoperative)...
August 2016: Lancet Oncology
Julie Berbis, Céline Reggio, Gérard Michel, Pascal Chastagner, Yves Bertrand, Justyna Kanold, Nicolas Sirvent, Dominique Plantaz, André Baruchel, Marie-Dominique Tabone, Floriane Garnier, Marie-Pascale Lehucher-Michel, Pascal Auquier
PURPOSE: Our principal aim was to assess the occupational outcomes of French survivors of childhood leukemia, compared to national population. The secondary objective was to identify determinants linked with employment stability after childhood leukemia. METHODS: All survivors aged 15 and over enrolled in the French LEA Cohort (Childhood and Adolescent Leukemia) were included. Occupational data were self-reported. The occupational distributions expected in the cohort for each age range were established based on the distribution in France as reference, and comparisons between observed and expected distributions were performed...
December 2016: Journal of Cancer Survivorship: Research and Practice
Delphine Rea, Shanti Ame, Aude Charbonnier, Valérie Coiteux, Pascale Cony-Makhoul, Martine Escoffre-Barbe, Gabriel Etienne, Martine Gardembas, Agnès Guerci-Bresler, Laurence Legros, Franck Nicolini, Michel Tulliez, Eric Hermet, Françoise Huguet, Hyacinthe Johnson-Ansah, Simona Lapusan, Philippe Quittet, Philippe Rousselot, François-Xavier Mahon, Emmanuel Messas
Tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein represent an outstanding progress in chronic myeloid leukemia and long-term progression-free survival has become a reality for a majority of patients. However, tyrosine kinase inhibitors may at best chronicize rather than cure the disease thus current recommendation is to pursue treatment indefinitely. As a consequence, high quality treatment and care must integrate optimal disease control and treatment tolerability. Tyrosine kinase inhibitors have an overall favorable safety profile in clinical practice since most adverse events are mild to moderate in intensity...
February 2016: Bulletin du Cancer
Hervé Ghesquieres, Susan L Slager, Fabrice Jardin, Amelie S Veron, Yan W Asmann, Matthew J Maurer, Thierry Fest, Thomas M Habermann, Marie C Bene, Anne J Novak, Sylvain Mareschal, Corinne Haioun, Thierry Lamy, Stephen M Ansell, Herve Tilly, Thomas E Witzig, George J Weiner, Andrew L Feldman, Ahmet Dogan, Julie M Cunningham, Curtis L Olswold, Thierry Jo Molina, Brian K Link, Noel Milpied, David G Cox, Gilles A Salles, James R Cerhan
PURPOSE: We performed a multistage genome-wide association study to identify inherited genetic variants that predict outcome in diffuse large B-cell lymphoma patients treated with immunochemotherapy. METHODS: We conducted a meta-analysis of two genome-wide association study data sets, one from the LNH2003B trial (N = 540), a prospective clinical trial from the Lymphoma Study Association, and the other from the Molecular Epidemiology Resource study (N = 312), a prospective observational study from the University of Iowa-Mayo Clinic Lymphoma Specialized Program of Research Excellence...
November 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Meryl Horwitz, Christelle Dufour, Pierre Leblond, Franck Bourdeaut, Cécile Faure-Conter, Anne-Isabelle Bertozzi, Marie Bernadette Delisle, Gilles Palenzuela, Anne Jouvet, Didier Scavarda, Matthieu Vinchon, Laetitia Padovani, Jean Gaudart, Dominique Figarella Branger, Nicolas Andre
PURPOSES: The purpose of this study was to retrospectively study embryonal tumors with multilayered rosettes (ETMR), a rare new entity that gathers ETAN-TR (embryonal tumor with abundant neuropil and true rosettes), ependymoblastomas, and medulloepitheliomas, in order to improve their descriptions and try to better define therapeutic modalities. METHODS: Patients with ETMR, ETAN-TR, ependymoblastoma, and medulloepithelioma treated in SFCE centres (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent) since 2000 were collected...
February 2016: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
Fabio Efficace, Gianluca Gaidano, Massimo Breccia, Maria Teresa Voso, Francesco Cottone, Emanuele Angelucci, Giovanni Caocci, Reinhard Stauder, Dominik Selleslag, Mirjam Sprangers, Uwe Platzbecker, Alessandra Ricco, Grazia Sanpaolo, Odile Beyne-Rauzy, Francesco Buccisano, Giuseppe A Palumbo, David Bowen, Khanh Nguyen, Pasquale Niscola, Marco Vignetti, Franco Mandelli
BACKGROUND: The clinical presentation of myelodysplastic syndromes is highly variable and so accurate prediction of outcomes in these patients is crucial. We aimed to assess whether self-reported fatigue severity predicts overall survival beyond gold-standard prognostic indices in patients with higher-risk myelodysplastic syndromes. METHODS: We did a multicentre, prospective, observational, cohort study of patients from 37 centres in Europe, USA, and east Asia. Adults (≥18 years) with myelodysplastic syndromes were consecutively enrolled within 6 months of diagnosis with an intermediate-2-risk or high-risk score according to the International Prognostic Scoring System (IPSS)...
November 2015: Lancet Oncology
Caroline Mayeur-Rousse, Julien Guy, Laurent Miguet, Sabrina Bouyer, Franck Geneviève, Nelly Robillard, Françoise Solly, Aida Maar, Marie C Bené, Laurent Mauvieux
CD180, a related member of the Toll-like receptor family, is lost or underexpressed at the plasma membrane in circulating cells of various B-cell lymphomas except marginal zone lymphomas (MZL). In order to confirm its clinical relevance in routine analysis, we evaluated prospectively the expression of CD180 in 236 patients from 5 French University Hospital laboratories on behalf of the GEIL. Highly comparable results were obtained in all centers using the EuroFlow standardization protocol. We observed that CD180 median fluorescence (MdFI) was significantly higher in MZL and hairy cell leukaemia (HCL) compared to all other B-cell proliferations (P < 0...
September 2016: Cytometry. Part B, Clinical Cytometry
Eva de Berranger, Charlotte Jubert, Gérard Michel
Under the long-term monitoring of patients treated in childhood or adolescence for cancer, we present in this article the long-term monitoring and therefore possible effects of patients who underwent allergenic hematopoietic stem cell transplantation. This article is based on a collaborative effort organized by the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC), which took place during the 4th day of allograft harmonization practices. Patients affected are children and young adults (0-25 years)...
July 2015: Bulletin du Cancer
Meryl Horwitz, Pascal Auquier, Vincent Barlogis, Audrey Contet, Maryline Poiree, Justyna Kanold, Yves Bertrand, Dominique Plantaz, Claire Galambrun, Julie Berbis, Virginie Villes, Pascal Chastagner, Nicolas Sirvent, Claire Oudin, Gérard Michel
Cataract was prospectively assessed by serial slip lamp tests in 271 patients included in the Leucémie Enfants Adolescents (LEA) programme, the French cohort of childhood leukaemia survivors. All had received haematopoietic stem cell transplantation (HSCT) after total body irradiation (TBI, n = 201) or busulfan-based (n = 70) myeloablative conditioning regimen. TBI was fractionated in all but six patients. The mean duration of follow-up from HSCT was 10·3 years. Cataract was observed in 113/271 patients (41·7%); 9/113 (8·1%) needed surgery...
February 2015: British Journal of Haematology
D Rossille, M Gressier, D Damotte, D Maucort-Boulch, C Pangault, G Semana, S Le Gouill, C Haioun, K Tarte, T Lamy, N Milpied, T Fest
The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of adults with cancer has never been performed in a prospective patient cohort. We evaluated the clinical impact of sPD-L1 level measured at the time of diagnosis for newly diagnosed diffuse large B-cell lymphoma (DLBCL). Soluble PD-L1 was measured in the plasma of 288 patients enrolled in a multicenter, randomized phase III trial that compared R-high-dose chemotherapy with R-CHOP. The median follow-up was 41.4 months. A cutoff of 1...
December 2014: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Julie Berbis, Gérard Michel, André Baruchel, Yves Bertrand, Pascal Chastagner, François Demeocq, Justyna Kanold, Guy Leverger, Dominique Plantaz, Marilyne Poirée, Jean-Louis Stephan, Pascal Auquier, Audrey Contet, Jean-Hugues Dalle, Stéphane Ducassou, Virginie Gandemer, Patrick Lutz, Nicolas Sirvent, Marie-Dominique Tabone, Sandrine Thouvenin-Doulet
The main aim of the Leucémies de l'Enfant et l'Adolescent (LEA) project (Childhood and Adolescent Leukaemia) is to study the determinants (medical, socioeconomic, behavioural and environmental) of medium- and long-term outcomes of patients treated for childhood acute leukaemia (AL). The LEA study began in 2004 and is based on a French multicentric prospective cohort. Included are children treated for AL since January 1980 (incident and prevalent cases), surviving at month 24 for myeloblastic AL and lymphoblastic AL grafted in first complete remission or at month 48 for lymphoblastic AL not grafted in first complete remission...
February 2015: International Journal of Epidemiology
Sylvain Thépot, Raphael Itzykson, Valerie Seegers, Christian Recher, Emmanuel Raffoux, Bruno Quesnel, Jacques Delaunay, Thomas Cluzeau, Anne Marfaing Koka, Aspasia Stamatoullas, Marie-Pierre Chaury, Caroline Dartigeas, Stéphane Cheze, Anne Banos, Pierre Morel, Isabelle Plantier, Anne-Laure Taksin, Jean Pierre Marolleau, Cecile Pautas, Xavier Thomas, Francoise Isnard, Blandine Beve, Yasmine Chait, Agnes Guerci, Norbert Vey, Francois Dreyfus, Lionel Ades, Norbert Ifrah, Herve Dombret, Pierre Fenaux, Claude Gardin
Limited data are available on azacitidine (AZA) treatment and its prognostic factors in acute myeloid leukemia (AML). One hundred and forty-nine previously untreated AML patients considered ineligible for intensive chemotherapy received AZA in a compassionate patient-named program. AML diagnosis was de novo, post-myelodysplastic syndromes (MDS), post-MPN, and therapy-related AML in 51, 55, 13, and 30 patients, respectively. Median age was 74 years, median white blood cell count (WBC) was 3.2 × 10⁹ /L and 58% of the patients had ≥ 30% marrow blasts...
April 2014: American Journal of Hematology
Sarah Bertoli, Pierre Bories, Marie C Béné, Sylvie Daliphard, Bruno Lioure, Arnaud Pigneux, Norbert Vey, Jacques Delaunay, Vincent Leymarie, Isabelle Luquet, Odile Blanchet, Pascale Cornillet-Lefebvre, Mathilde Hunault, Didier Bouscary, Nathalie Fegueux, Philippe Guardiola, François Dreyfus, Jean Luc Harousseau, Jean Yves Cahn, Norbert Ifrah, Christian Récher
Early response to chemotherapy has a major prognostic impact in acute myeloid leukemia patients treated with a double induction strategy. Less is known about patients treated with standard-dose cytarabine and anthracycline. We designed a risk-adapted remission induction regimen in which a second course of intermediate-dose cytarabine was delivered after standard "7+3" only if patients had 5% or more bone marrow blasts 15 days after chemotherapy initiation (d15-blasts). Of 823 included patients, 795 (96.6%) were evaluable...
January 2014: Haematologica
Francesco Lo-Coco, Giuseppe Avvisati, Marco Vignetti, Christian Thiede, Sonia Maria Orlando, Simona Iacobelli, Felicetto Ferrara, Paola Fazi, Laura Cicconi, Eros Di Bona, Giorgina Specchia, Simona Sica, Mariadomenica Divona, Alessandro Levis, Walter Fiedler, Elisa Cerqui, Massimo Breccia, Giuseppe Fioritoni, Helmut R Salih, Mario Cazzola, Lorella Melillo, Angelo M Carella, Christian H Brandts, Enrica Morra, Marie von Lilienfeld-Toal, Bernd Hertenstein, Mohammed Wattad, Michael Lübbert, Matthias Hänel, Norbert Schmitz, Hartmut Link, Maria Grazia Kropp, Alessandro Rambaldi, Giorgio La Nasa, Mario Luppi, Fabio Ciceri, Olimpia Finizio, Adriano Venditti, Francesco Fabbiano, Konstanze Döhner, Michaela Sauer, Arnold Ganser, Sergio Amadori, Franco Mandelli, Hartmut Döhner, Gerhard Ehninger, Richard F Schlenk, Uwe Platzbecker
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter)...
July 11, 2013: New England Journal of Medicine
Emmanuel Gyan, Diane Damotte, Stéphane Courby, Delphine Sénécal, Philippe Quittet, Aline Schmidt-Tanguy, Anne Banos, Steven Le Gouill, Thierry Lamy, Jean Fontan, Hervé Maisonneuve, Magda Alexis, Francois Dreyfus, Olivier Tournilhac, Kamel Laribi, Philippe Solal-Céligny, Nina Arakelyan, Guillaume Cartron, Remy Gressin
The optimal management of relapsed diffuse large B-cell lymphoma (DLBCL) is not standardized. The Groupe Ouest Est des Leucémies et aAutres Maladies du Sang developed a combination of vinorelbine, ifosfamide, mitoxantrone and prednisone (NIMP) for the treatment of relapsed DLBCL, and assessed its efficacy and safety in association with rituximab (R). This multicentric phase II study included 50 patients with DLBCL in first relapse, aged 18-75 years. Patients received rituximab 375 mg/m² day 1, ifosfamide 1000 mg/m² days 1-5, vinorelbine 25 mg/m² days 1 and 15, mitoxantrone 10 mg/m² day 1, and prednisone 1 mg/kg days 1-5, every 28 days for three cycles...
July 2013: British Journal of Haematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"